OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Frequently asked questions
What sector does OptiNose Inc (0OP) operate in?
OptiNose Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is OptiNose Inc (0OP) current stock price?
As of the latest data, OptiNose Inc stock price is €5.10, with a previous close of €5.10.
What is OptiNose Inc (0OP) current market capitalization?
OptiNose Inc market cap is approximately 51.28 million.
What is OptiNose Inc (0OP) Earnings Per Share (EPS)?
The trailing EPS is -€4.17.
Does OptiNose Inc (0OP) pay dividends?
No. OptiNose Inc does not pay a dividend.
What is OptiNose Inc (0OP) beta (volatility) score?
OptiNose Inc has a beta of -0.068, indicating lower volatility than the overall market.
